Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular. The ADAP average annual return since 2015 is shown above.
The Average Annual Return on the ADAP average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ADAP average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADAP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|